DiamiR Biosciences and Aptorum Group Receive Approval from New York State for DiamiR's APOE Genotyping Test

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 20 2025

0mins

Source: Globenewswire

DiamiR Receives Approval: DiamiR Biosciences Corp. has received Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health, allowing it to offer testing through licensed healthcare providers.
Importance of APOE Testing: The APOE test identifies genetic variants linked to late-onset Alzheimer's disease, with the APOE ε4 allele being a significant risk factor. It aids in risk assessment and personalized care strategies for cognitive decline.
Merger Announcement: DiamiR is set to merge with Aptorum Group Limited, with the transaction expected to close in Q4 2025, subject to stockholder approval and customary conditions.
Focus on Brain Health Diagnostics: DiamiR specializes in minimally invasive tests for brain health, utilizing microRNA signatures in blood plasma, and aims to expand its portfolio of molecular tests for neurodegenerative diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free